.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
UBS
Fuji
Cantor Fitzgerald
Julphar
Fish and Richardson
Healthtrust
AstraZeneca
Cipla
Medtronic

Generated: September 22, 2017

DrugPatentWatch Database Preview

RITALIN LA Drug Profile

« Back to Dashboard

Which patents cover Ritalin La, and what generic Ritalin La alternatives are available?

Ritalin La is a drug marketed by Novartis and is included in one NDA. There is one patent protecting this drug and two Paragraph IV challenges.

This drug has one hundred and forty patent family members in thirty-three countries.

The generic ingredient in RITALIN LA is methylphenidate hydrochloride. There are thirty-one drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the methylphenidate hydrochloride profile page.

Summary for Tradename: RITALIN LA

Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Bulk Api Vendors: see list44
Clinical Trials: see list60
Patent Applications: see list2,430
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:RITALIN LA at DailyMed

Pharmacology for Tradename: RITALIN LA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis
RITALIN LA
methylphenidate hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021284-004Apr 10, 2004AB1RXYesNo► Subscribe► SubscribeY ► Subscribe
Novartis
RITALIN LA
methylphenidate hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021284-003Jun 5, 2002AB1RXYesNo► Subscribe► SubscribeY ► Subscribe
Novartis
RITALIN LA
methylphenidate hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021284-001Jun 5, 2002AB1RXYesNo► Subscribe► SubscribeY ► Subscribe
Novartis
RITALIN LA
methylphenidate hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021284-002Jun 5, 2002AB1RXYesNo► Subscribe► SubscribeY ► Subscribe
Novartis
RITALIN LA
methylphenidate hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021284-005Oct 27, 2014DISCNYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: RITALIN LA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis
RITALIN LA
methylphenidate hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021284-003Jun 5, 2002► Subscribe► Subscribe
Novartis
RITALIN LA
methylphenidate hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021284-003Jun 5, 2002► Subscribe► Subscribe
Novartis
RITALIN LA
methylphenidate hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021284-004Apr 10, 2004► Subscribe► Subscribe
Novartis
RITALIN LA
methylphenidate hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021284-001Jun 5, 2002► Subscribe► Subscribe
Novartis
RITALIN LA
methylphenidate hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021284-001Jun 5, 2002► Subscribe► Subscribe
Novartis
RITALIN LA
methylphenidate hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021284-004Apr 10, 2004► Subscribe► Subscribe
Novartis
RITALIN LA
methylphenidate hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021284-003Jun 5, 2002► Subscribe► Subscribe
Novartis
RITALIN LA
methylphenidate hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021284-002Jun 5, 2002► Subscribe► Subscribe
Novartis
RITALIN LA
methylphenidate hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021284-002Jun 5, 2002► Subscribe► Subscribe
Novartis
RITALIN LA
methylphenidate hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021284-004Apr 10, 2004► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: RITALIN LA

Drugname Dosage Strength RLD Submissiondate
metformin hydrochlorideExtended-release Capsules10 mgRitalin LA5/21/2007
metformin hydrochlorideExtended-release Capsules20 mg, 30 mg and 40 mgRitalin LA8/21/2006

Non-Orange Book Patents for Tradename: RITALIN LA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,730,325 Multiparticulate modified release composition► Subscribe
8,119,163Nanoparticulate and controlled release compositions comprising cefditoren► Subscribe
7,580,712Wireless high-speed data network planning tool► Subscribe
6,902,742 Multiparticulate modified release composition► Subscribe
6,793,936 Multiparticulate modified release composition► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: RITALIN LA

Country Document Number Estimated Expiration
Hungary230454► Subscribe
China100444830► Subscribe
European Patent Office1126826► Subscribe
Mexico2007007942► Subscribe
Australia2004202078► Subscribe
Japan2008545808► Subscribe
Canada2611938► Subscribe
Australia2006343445► Subscribe
Portugal1126826► Subscribe
Hong Kong1117060► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Fish and Richardson
Cerilliant
Colorcon
Baxter
Daiichi Sankyo
Chubb
Farmers Insurance
Fuji
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot